Citations

Clear

9383 citation(s) found for "Thomas, PS".

Secukinumab in the Treatment of Moderate‐to‐Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phas
Alavi, Afsáneh , Reguiaï, Z. , Gottlieb, Alice B. , Wozniak, Magdalena B. , Uhlmann, Lorenz , Fan, Heng , Martinez, Angela Llobet, Thomas, Nicolas, Alarcón, Ivette , Bieth, Bruno, Ravichandran, Shoba, Reguiai, Ziad , Alavi, A , Jemec, Gregor B. E. , Bruin, Gerard J. M. , Thomas, Nicolas, Kimball, Alexa B.

Mayo Clinic

International Journal of Dermatology | August 21, 2025 | Volume: 65 | Issue: 2 | Pages: 289-298

10.1111/ijd.70025 | PMID 40839197 Get It

ABSTRACT Background Secukinumab, a fully human, monoclonal antibody targeting interleukin‐17A, is approved for moderate‐to‐severe HS in adults. This study evaluated pharmacokinetics (PK), high‐sensitivity C‐reactive protein (hsCRP) changes, and safety of secukinumab over 52 weeks in SUNSHINE and SUNRISE Phase 3 trials. Methods An exploratory analysis of pooled Phase‐3 trials evaluated serum PK and safety of secukinumab 300 mg every 2 (SECQ2W) or 4 weeks (SECQ4W). A population PK model assessed the effects of body weight, disease severity, and baseline hsCRP on secukinumab serum concentration. Exposure–response analysis assessed the relationship between predicted PK and HS clinical response [HiSCR]. No confirmatory statistical testing was performed. Results Mean serum trough concentration at Weeks 16, 24, and 52 was ~2‐fold higher with SECQ2W vs. SECQ4W. At Week 16, exposure overlap was high, with an estimated numerical increase in HiSCR of ~3% for SECQ2W over SECQ4W. At Week 52, HiSCR levels plateaued. At Week 16, hsCRP decreased from 18.6 ± 26.3 mg/L to 12.8 ± 18.0 mg/L (SECQ2W), 15.9 ± 27.6 mg/L to 11.5 ± 18.4 mg/L (SECQ4W), and remained unchanged with placebo (14.4 ± 22.5 mg/L to 14.7 ± 23.8 mg/L); reductions were sustained through Week 52. Higher body weight, disease severity, and baseline hsCRP were associated with lower secukinumab serum concentrations. Secukinumab immunogenicity was low (< 1%), with no new safety signals. Conclusion Secukinumab serum concentrations in patients with HS varied with body weight, disease severity, and baseline hsCRP. SECQ2W may benefit certain patients. Secukinumab reduced hsCRP through Week 52. The safety profile of secukinumab was consistent with other approved indications, with no apparent dose–response relationship observed. Trial Registration NCT03713619 (Novartis study code CAIN457M2301). NCT03713632 (Novartis study code CAIN457M2302)
Paclitaxel neurotoxicity is triggered by epidermal EG5 dependent microtubule fasciculation and X-ROS formation
Rieger, Sandra , Hsieh, Chia-Jung , Anthony, C. Merlyn , Vlach, Mikaela , Cádiz, Antonio , Schmidt, Natalie A. , Ugo, Marie J, Sanchez, Celina Amaya , Reimonn, Cassandra, Wuchty, Stefan , Pellegrini, Adriana D., Brieger, Leah, Pappalardo, Leah G, Regan, Daniel P. , Zhao, Bowen , Dasari, Surendra , Capobianco, Enrico , Lisse, Thomas S. , Staff, Nathan P. , Xu, Xiang‐Xi , Gutierrez, Sergio, Li, Xin , Vlach, Mikaela R , Diaz, Antonio Cadiz , Schmidt, Natalie A , Amaya Sanchez, Maria Celina , Reimonn, Cassandra A , Wuchty, Stefan , Regan, Daniel P , Zhao, Bowen , Zhang, Fuwu , Howell, Caitlin , Hrstka, Sybil C , Dasari, Surendra , Capobianco, Enrico , Lisse, Thomas S , Staff, Nathan P , Xu, Mike Xiangxi , Rieger, Sandra , Hrstka, Sybil , Harrison, Benjamin J. , Gutierrez, Sergio, Li, Xin

Mayo Clinic

No container title available | August 20, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5470731/v1 | PMID 40894047 Get It

Abstract Taxanes are frontline chemotherapeutics that stabilize microtubules, induce mitotic arrest, and drive tumor remission. However, their off-target effects in healthy tissues, most notably cutaneous axon degeneration underlying chemotherapy-induced peripheral neuropathy (CIPN), remain poorly understood. Here, we show that paclitaxel induces microtubule fasciculation in epidermal keratinocytes through the mitotic kinesin Eg5, thereby initiating CIPN. Mechanistically, paclitaxel enhances Eg5-dependent fasciculation of detyrosinated (stabilized) microtubules, which constrict and breach the nuclear lamina. This deformation triggers tension-dependent NADPH oxidase-mediated nuclear ROS (X-ROS) formation upstream of mmp13 transcription, a pathway we previously demonstrated drives sensory axon degeneration. Employing a cross-species framework spanning zebrafish, mice, human skin biopsies, and a breast adenocarcinoma cell line, we uncover a conserved paclitaxel–Eg5 mechanism leading to fasciculation of stable microtubules in both healthy epidermis and cancer cells. These findings highlight the dualistic nature of paclitaxel action and underscore the challenge of preserving anticancer efficacy while preventing neurotoxic side effects.
Cerebellum mitochondrial DNA copy number is increased in Parkinson’s disease
Beglarian, Talia , Tyrpak, David R. , MacKay, J. Andrew , Scholz, Sonja W. , Albert, Marilyn S. , Dawson, Ted M. , Troncoso, Juan C. , Hernandez, Dena G., Cookson, Mark R , Singleton, Andrew B., Beach, Thomas G., Hjelm, Brooke E. , MacKay, John Andrew , Scholz, Sonja W , Dawson, Ted M , Cookson, Mark , Adler, C H , Serrano, Geidy E , Hjelm, Brooke E , Gibbs, J. Raphael , Traynor, Bryan J , Rosenthal, Liana S. , Adler, Charles H. , Serrano, Geidy E. , Singleton, Andrew B., Beach, Thomas G.

Mayo Clinic

Brain Communications | August 20, 2025 | Volume: 7 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcaf296 | PMID 40873892 Get It

Abstract Bioinformatics methods can be used to quantify mitochondrial DNA copy number from whole genome sequencing (WGS) data. We evaluated mitochondrial DNA copy number from human brain-derived WGS data using the fastMitoCalc tool. 341 Parkinson’s Disease cerebellum samples were compared with 74 age-matched controls from the North American Brain Expression Consortium. Parkinson’s Disease cerebellum had significantly higher mitochondrial DNA copy number compared with controls (P = 4.15e–7), and this effect was reproducible in four of five brain banks when analysis was restricted to each resource that contributed Parkinson’s Disease samples to this genetic dataset. Follow-on analyses of 128 Parkinson’s Disease cerebellum samples and 33 controls that had paired neuropathology data and clinical scores demonstrated a significant increase in mitochondrial DNA copy number with Unified Staging System for Lewy Body disorders stages and Unified Parkinson’s Disease Rating Scale (off meds) motor scores. Analysis of Lewy Body scores from ten brain regions showed cerebellum mitochondrial DNA copy number increased upon pathological infestation of α-synuclein aggregates in the brainstem and limbic system but did not increase after late-stage neocortical involvement. This genetics dataset supports previous observations of cerebellum activation in Parkinson’s Disease and suggests mitochondrial DNA copy number may increase to support this regional activation as a compensatory mechanism to pathology or motor symptoms.
Advancements in Inlay Glenoid Components for Anatomic Total Shoulder Arthroplasty: A Review
Reddy, Akshay , Hones, Keegan M. , Rakauskas, Taylor R. , King, Joseph J. , Wright, Thomas W., Hao, Kévin A. , Reddy, Akshay R , Hao, Kevin A , King, Joseph J , Hones, Keegan M , Wright, Thomas W. , Schoch, Bradley S.

Mayo Clinic

Journal of Clinical Medicine | August 18, 2025 | Volume: 14 | Issue: 16 | Pages: 5820

10.3390/jcm14165820 | PMID 40869646 Get It

While anatomic total shoulder arthroplasty is a successful procedure that provides reliable pain relief and restoration of function in most patients, its success has been limited by glenoid component loosening. While series reporting the outcomes of inlay glenoid components have demonstrated excellent clinical outcomes with low rates of component loosening and need for revision, surgeons have been hesitant to adopt these implants due to concerns of inadequate pain relief secondary to the remaining glenoid rim contacting the humeral head implant. The inset glenoid component, a variant of the traditional inlay components, has gained interest because its design aims to achieve similar stability to traditional inlay components through implantation within strong subchondral bone, reduce the amount of glenoid vault removed compared to inlay components, and has a glenoid face designed to limit the rocking-horse phenomenon. In limited series, the inset glenoid component has demonstrated superior biomechanical and clinical performance compared to traditional onlay glenoid components. Although there have been minimal clinical studies investigating the inset glenoid in comparison to onlay and inlay components to date, a subset of case series with short-term follow-up have demonstrated favorable outcomes. The purpose of this article was to review the design rationale, biomechanical evidence, and clinical performance of the inset glenoid component.
GLP ‐ 1RA Semaglutide Delays the Progression of ADPKD Through Regulation of Glycolysis, Mitochondria Function and Ketosis
Wu, Jiao , Cheng, Alice, Harris, Peter C. , Zhou, Julie , Cheng, Alice Shasha, Zhou, Julie Xia, Harris, Peter C , Weimbs, Thomas , Li, Xiaogang

Mayo Clinic

The FASEB Journal | August 15, 2025 | Volume: 39 | Issue: 16 | Pages: No page available

10.1096/fj.202501605r | PMID 40815122 Get It

ABSTRACT Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease that is caused by mutations in PKD genes. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (GLP‐1RAs) are a class of medications that mimic the actions of the hormone GLP‐1, conferring beneficial effects on weight management and other metabolic conditions. However, whether GLP‐1RA plays a kidney‐protective action in ADPKD remains unknown. In this study, we define the role and mechanisms of one of the most popular GLP‐1RA agonists, Semaglutide, in ADPKD. We show that the expression of GLP‐1R is decreased in Pkd1 mutant renal epithelial cells and kidneys. Treatment with Semaglutide delays cyst growth in aggressive and long‐lasting Pkd1 mutant mouse models. Treatment with Semaglutide (1) decreases glucose uptake, ATP generation, and glycolysis, (2) deactivates PKD‐associated signaling pathways, including Rb, S6, and Stat3, resulting in a decrease in cell proliferation, (3) deactivates NF‐kB signaling pathways, resulting in a decrease in the expression of cytokines and the recruitment of macrophages, (4) normalizes mitochondrial morphology and function, (5) induces Pkd1 mutant renal epithelial cell death, (6) induces ketosis characterized by an increase in serum level of beta‐hydroxybutyrate (BHB) and the activation of AMPK, and (7) alleviates renal fibrosis through deactivation of TGF‐b signaling in Pkd1 mutant mouse kidneys. This study highlights the potential of GLP‐1R agonists as a novel therapeutic strategy for ADPKD treatment.
Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline
Agarwal, Arnav , Manja, Veena , Agoritsas, Thomas , MacDonald, Helen, Li, Sheyu , Rodríguez‐Gutiérrez, René , Heen, Anja Fog , Gabi, Jenan, Jeppesen, Britta Tendel, Jha, Vivekanand , Nagler, Evi, Odom, Adrienne, Rodondi, Nicolas, Wright, Robin, Vandvik, Per Olav , Agarwal, Arnav , Li, Sheyu , Mustafa, Reem A , Macdonald, Helen, Foroutan, Farid , Rayner, Daniel , Åsvold, Bjørn Olav , Guo, Lixin , Hao, Qiukui , Jeppesen, Britta Tendal, Rodondi, Nicolas , Shetty, Sahana , Vermandere, Mieke , Guyatt, Gordon

Mayo Clinic

BMJ | August 15, 2025 | Volume: 390 | Issue: No issue available | Pages: e082071

10.1136/bmj-2024-082071 | PMID 40813129 Get It

Abstract Clinical question What are the benefits and harms of medications for adults with type 2 diabetes at varied risks of cardiovascular and kidney related complications? Context Emerging clinical trials of novel medications have demonstrated benefits on cardiovascular, kidney, and weight related outcomes in people with type 2 diabetes. Dynamically updated practice guidelines adhering to standards of trustworthiness are necessary in response to a rapidly evolving evidence base and the availability of multiple medication alternatives. This living practice guideline incorporates the latest available medications and evidence and provides recommendations stratified by risks of cardiovascular and kidney complications to inform diabetes management. Recommendations The panel issued risk-stratified recommendations regarding four prioritised medications for adults with type 2 diabetes (SGLT-2 inhibitors, GLP-1 receptor agonists, finerenone and tirzepatide): • Lower risk (three or fewer cardiovascular risk factors without established cardiovascular disease (CVD) or chronic kidney disease (CKD)): weak recommendation against SGLT-2 inhibitors or GLP-1 receptor agonists. • Moderate risk (more than three cardiovascular risk factors without established CVD or CKD; or established CVD and/or CKD at lower risk of complications): weak recommendation in favour of SGLT-2 inhibitors or GLP-1 receptor agonists; and a weak recommendation against finerenone in adults with CKD. • Higher risk (established CVD and/or CKD at higher risk of complications, or established heart failure): strong recommendation in favour of SGLT-2 inhibitors or GLP-1 receptor agonists; and a weak recommendation in favour of finerenone in adults with CKD. • Across risk strata: weak recommendation in favour of tirzepatide in adults with obesity. About this guideline and how it was created An international panel including two patient partners, clinicians, and methodologists produced these recommendations. The panel followed standards for trustworthy guidelines and used the GRADE approach, explicitly considering the balance of benefits, harms and burdens of treatment from an individual patient perspective. Recommendations were informed by a linked living systematic review and network meta-analysis evaluating relative benefits and harms updated to 31 July 2024; and by linked systematic reviews addressing risk prediction models and values and preferences of adults with type 2 diabetes. Candidate therapeutics are prioritised based on availability of sufficient randomised trial data, relevance to a global audience and likelihood of changing practice. This is the first version of the living guideline. The guideline is part of the BMJ Rapid Recommendations series. MAGICapp displays the most recent version of the guideline and full content including evidence summaries and decision aids; major updates will be published in The BMJ . We encourage re-use, adaptation and translation of these living guidelines, and recognise that the lack of availability or high costs of some medications may be prohibitive and will impact on how these recommendations are implemented across different health care systems.
Non-DLBCL monomorphic and Hodgkin lymphoma PTLD: clinical insights and treatment strategies
Atallah‐Yunes, Suheil Albert , Khurana, Arushi , Atallah-Yunes, Albert , Habermann, Thomas M.

Mayo Clinic

Blood Advances | August 14, 2025 | Volume: 9 | Issue: 22 | Pages: 5792-5801

10.1182/bloodadvances.2025016930 | PMID 40811832 Get It

Abstract Monomorphic posttransplant lymphoproliferative disorders (PTLDs) beyond diffuse large B-cell lymphoma (DLBCL) are rare, biologically heterogeneous entities with limited prospective data to guide treatment. DLBCL-PTLD, which comprises most cases, is managed using approaches informed by prospective phase 2 studies, including reduction in immunosuppression and a risk-adapted sequential immunochemotherapy approach. In contrast, non-DLBCL subtypes such as Burkitt lymphoma, PTLDs of T/NK-cell origin, and plasmacytic variants are less common and are typically treated using strategies extrapolated from established treatment algorithms used in immunocompetent patients and sporadic case reports. Classic Hodgkin lymphoma PTLD, although not classified as monomorphic, represents another distinct and clinically relevant subtype. This review summarizes the epidemiology, clinical features, treatment strategies, and outcomes associated with these less common PTLDs, aiming to provide a practical framework for their management.
Liquid Adaptive AI: A Theoretical Framework for Continuously Self-Improving Artificial Intelligence
Caulfield, Thomas R. , Islam, Naeyma N., Chitale, Rohit, Caulfield, Thomas R , Islam, Naeyma N., Chitale, Rohit

Mayo Clinic

AI | August 14, 2025 | Volume: 6 | Issue: 8 | Pages: 186

10.3390/ai6080186 Get It

We present Liquid Adaptive AI as a theoretical framework and mathematical basis for artificial intelligence systems capable of continuous structural adaptation and autonomous capability development. This work explores the conceptual boundaries of adaptive AI by formalizing three interconnected mechanisms: (1) entropy-guided hyperdimensional knowledge graphs that could autonomously restructure based on information-theoretic criteria; (2) a self-development engine using hierarchical Bayesian optimization for runtime architecture modification; and (3) a federated multi-agent framework with emergent specialization through distributed reinforcement learning. We address fundamental limitations in current AI systems through mathematically formalized processes of dynamic parameter adjustment, structural self-modification, and cross-domain knowledge synthesis, while immediate implementation faces substantial computational challenges requiring infrastructure on the scale of current large language model training facilities, we provide architectural specifications, theoretical convergence bounds, and evaluation criteria as a foundation for future research. This theoretical exploration establishes mathematical foundations for a potential new paradigm in artificial intelligence that would transition from episodic training to persistent autonomous development, offering a long-term research direction for the field. A comprehensive Supplementary Materials document provides detailed technical analysis, computational requirements, and an incremental development roadmap spanning approximately a decade.
Brain signatures of nociplastic pain: Fibromyalgia Index and descending modulation at population level
Kelleher, Eoin , Wanigasekera, Vishvarani , Seymour, Ben , Segerdahl, Andrew R. , Irani, Anushka , Kelleher, Eoin M , Seymour, Ben , Segerdahl, Andrew Reilly , Irani, Anushka , Lange, Frederik , Rathod‐Mistry, Trishna , Nichols, Thomas E. , Tracey, Irene

Mayo Clinic

Brain | August 14, 2025 | Volume: 149 | Issue: 4 | Pages: 1365-1380

10.1093/brain/awaf307 | PMID 40819274 Get It

Abstract Nociplastic pain is defined by altered nociceptive processing in the absence of clear peripheral damage or somatosensory lesions. The Fibromyalgia Index (FMI), derived from the 2016 diagnostic criteria, is increasingly used as a marker of nociplastic pain severity in clinical studies, yet its neurobiological validity remains untested at scale. Using multimodal neuroimaging data from over 40 000 participants in UK Biobank, we examined whether FMI scores were associated with altered functional and structural connectivity within the descending pain modulatory system (DPMS), a brain network involved in endogenous pain control and implicated in nociplastic pain conditions. Functional connectivity was assessed using resting-state functional MRI (rfMRI), and structural connectivity using diffusion-weighted MRI (dMRI) tractography. Connectivity was quantified between seven DPMS regions: periaqueductal grey (PAG), rostral ventromedial medulla (RVM), hypothalamus, amygdala, rostral and subgenual anterior cingulate cortex (rACC, sgACC), and dorsolateral prefrontal cortex (dlPFC). Multi-group structural equation models tested associations between FMI scores and connectivity, stratified by chronic pain status. Mediation models evaluated which aspects of nociplastic pain accounted for the observed associations: widespread pain and SPACE symptoms (sleep disturbance, pain, affect, cognitive problems, and low energy). To assess specificity, we repeated analyses using the Douleur Neuropathique 4 (DN4), a measure of neuropathic pain, and average pain intensity as comparison outcomes. In 22 139 individuals with chronic pain (58% female; mean age 64.8, standard deviation 7.59), FMI scores were associated with altered structural connectivity between the PAG and amygdala [β = 0.023, 95% confidence interval (CI): 0.0087 to 0.039; Pcorr = 0.0125] and between the PAG and hypothalamus (β = −0.029, 95% CI: −0.043 to −0.015; Pcorr = 0.0013). Functional connectivity in the same circuits showed smaller effects. These associations were not observed in individuals without chronic pain. Mediation analyses revealed that PAG-amygdala and PAG-hypothalamus connectivity were partially explained by fatigue, sleep duration, and widespread pain. DPMS connectivity was not significantly associated with neuropathic pain or average pain intensity. These findings suggest that FMI scores reflect biologically meaningful changes in brain connectivity, particularly in subcortical DPMS circuits implicated in affective and homeostatic dimensions of pain. Structural connectivity was more strongly associated with FMI than functional measures, possibly reflecting cumulative effects of chronic pain on white matter architecture. The absence of similar associations for other pain outcomes supports the specificity of FMI as a marker of nociplastic pain severity. These results provide a neurobiological basis for the FMI and support its use in population research and biomarker development for nociplastic pain.
Representation of Skin of Color in Cutaneous Oncology Publications: A Decade of Trends and Disparities
Amjad, Sarah , Cravero, Karen , Marks, Lisa , Degesys, Catherine A. , Barbosa, Naiara S. , Amjad, Sarah A , Marks, Lisa A

Mayo Clinic

International Journal of Dermatology | August 14, 2025 | Volume: 65 | Issue: 4 | Pages: 813-815

10.1111/ijd.70011 | PMID 40928140 Get It